Avid Bioservices Inc (CDMO)

[cjgaddy]

Entdoc, Bavi & FH-Bavi both require B2GP1 to bind to PS. PGN632 (DukeHIV/Genentech-Imaging) is B2GP1-Independent, as are next-gen. Betabodies…

• PGN635 is Fully-Human Bavituximab=1N11=AT004 (B2GPI-depen.); Genentech studying 89Zr-PGN635 as a Tumor Imaging Agent, “indep. of cancer type”
• PGN632 is the Duke-PPHM-HIV candidate=11.31=AT005 (B2GPI-indep.); also being studied by PPHM+LSU vs. Ocular Herpes (Acute HSV-1 Keratitis), see http://tinyurl.com/cax9a4p
• PGN650 is a human F(ab’)2 fragment that targets PS expression (1st ref’d in AACR’12 #2452) – see http://tinyurl.com/76nqqkm . 124I-PGN650 is Peregrine’s PS-Imaging candidate, whose IND clinical filing was announced 4-3-12, and whose n=12 trial started 6-2012.
- - - - - - - - -
Note: PGN632 (Duke/HIV preclin’s) binds to PS indep. of B2-glycoprotein I (B2GPI), unlike Bavi & FH-Bavituximab(PGN635) which depend on B2GPI as a binding intermediary.

Betabodies overview (7-6-13): http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89680206

= = = = = = = =
PS is immunosuppressive
PS is exploited by genetically diverse pathogens
PS is a valid therapeutic target
3 articles by Peter M. Henson (Natl-Jewish/Denver) about the immunosuppressive effects of exposed Phosphatidylserine (PS):
• 2-2005: “Interaction between PS & PS Receptor Inhibits Immune Responses In Vivo”, Peter Hoffmann http://www.jimmunol.org/cgi/content/full/174/3/1393
• 1-2002: ”PS-Dep. Ingestion of Apoptotic Cells Promotes TGF-B1 Secretion & Resolution of Inflammation”, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC150814
• 2-1998: ”Macrophages That Have Ingested Apoptotic Cells In Vitro Inhibit Pro-Inflammatory Cytokine Production…” http://www.jci.org/articles/view/1112/files/pdf
Peregrine’s Bavituximab generates full immune response against cancer
by reversing the inhibitory effect of PS on dendritic cells (DC)…

10-2012 Thorpe Diagram of Bavi-PGN635-PGN650 mabs – from SITC Annual Meeting, Bethesda MD: